SpecificationsOrganism/cell line/tissue*Homo sapiens*StrainPatient\'s colorectal tumor and adjacent normalmucosaSexBoth male and femaleArray typeAffymetrix CytoScan HDData formatRaw data: CEL files, processed data: Excel tableExperimental factorsTumor vs. normalExperimental featuresTumor and normal samples compared for copy number aberrations, loss of heterozygosity, uniparental disomy, GISTIC analysis miRNA target prediction, effect on transcription factor binding sites, functional analysis, pathway and network analysis, biomarker analysisSample source locationNational Guard Hospital, Riyadh, Saudi ArabiaConsentAll patients consented before starting the study

Direct link to deposited data {#s0050}
=============================

Deposited data can be found at <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE47204>.

Experimental design, materials and methods {#s0010}
==========================================

We carried out patient specific comparison of tumor and normal samples. Each patient\'s tumor microarray profile was compared against its own normal profile. Copy number variation, loss of heterozygosity and uniparental disomy were studied and the affected genes were analyzed.

Sample collection {#s0015}
-----------------

Biopsies were collected from Saudi Arabian patients presenting for preliminary CRC diagnosis. All cases were collected regardless of surgical stage or histologic grade. Each hematoxylin and eosin (H & E) stained case was reviewed by a board-certified pathologist to confirm the specimen\'s histological consistency with colon adenocarcinoma and that adjacent normal specimen contained no tumor cells. The sections were required to contain \> 60% tumor cell nuclei for inclusion in the study. The cohort consisted of patients who have not undergone any known CRC-related clinical intervention prior to the time of biopsy acquisition. Multiple biopsies were taken from the normal and tumor tissues. All the patient samples were collected from a single hospital.

Sample processing & DNA extraction {#s0020}
----------------------------------

Paired samples of tumor and adjacent normal mucosa taken from \> 2 cm apart were collected. Each tumor specimen weighed between 10 and 30 mg. The biopsy tissue was stored in RNAlater (Ambion) at 4 °C for 24 h, followed by freezing and further storage at − 20 °C [@bb0005]. CRC-positive sample pairs were then selected for DNA extraction by NucleoSpin Trio Kit (Macherey-Nagel, Germany) [@bb0010]. 10--30 mg tissue was homogenized using TissueLyser and stainless steel beads from Qiagen. Quality and quantity checks were carried out by Nanodrop (Thermo Fischer Scientific).

Data generation using cytogenetic array {#s0025}
---------------------------------------

CytoScan HD arrays along with a complete kit were acquired from Affymetrix (Affymetrix Inc., USA). The recommended DNA amplification kit was obtained from Clontech (Clontech Laboratories Inc., USA). The supplier\'s protocol was followed for the amplification, hybridization, washing and staining steps. Quality control after PCR amplification ([Fig. 1](#f0005){ref-type="fig"}) and fragmentation ([Fig. 2](#f0010){ref-type="fig"}) was carried out using agarose gel electrophoresis. The arrays were scanned using a 30007G scanner from Affymetrix.

Data analysis {#s0030}
-------------

We followed a case--control analysis strategy where the subject served as the donor of both control and tumor tissues. The tumor--normal comparisons were thus carried out between homogenous samples.

CNV, LOH and UPD analyses {#s0035}
-------------------------

Nexus Copy Number 6.0 (Biodiscovery, Inc., CA, USA) was used to assess genome wide copy number frequencies for the 15 patients. Furthermore, Aroma.affymetrix -- another CBS implementation as part of the BioConductor\'s DNACopy library and the associated TumorBoost algorithm (which normalize allele specific copy numbers for tumor samples with paired normal) -- was also used to identify genomic events. We obtained conforming results from both implementations. The combination of CytoScan HD\'s high resolution and in depth analysis by Nexus Copy Number allows us to capture even the smallest genomic events. All the samples had a quality score of \< 0.2 ([Table 1](#t0005){ref-type="table"}). The frequency threshold parameters used for the analysis are 0.2 for gain, 0.6 for high gain, − 0.2 for slight loss and − 1.0 for big loss. A minimum cutoff of 500 kb was used for detecting these events.

Information regarding transcription factor binding sites was obtained from the Open Regulatory Annotation Database (ORegAnno, [www.oreganno.org](http://www.oreganno.org){#ir0035}).

miRNA target analysis was carried out using the microRNA integration system for target gene prediction (MIRSYSTEM) software version 20130328 available at <http://mirsystem.cgm.ntu.edu.tw/>.

GISTIC analysis {#s0040}
---------------

Combining GISTIC (Genomic Identification of Significant Targets in Cancer) score ranking and peaks in copy numbers of genomic regions, we identified the genes according to the annotation of the human genome assembly GRCh37/hg19.

Through Nexus Copy Number, we carried out GISTIC analysis. G-scores relay the significance of genes to drive cancer by weighing regions of aberration against the likelihood for random occurrence. The G-scores for regions detected by CBS were examined. We labeled as significant any region of a score above 2.

Biomarker discovery {#s0045}
-------------------

We analyzed 144 genes identified through GISTIC for their potential role as biomarkers in human cancer. 31 genes were identified as potential biomarkers ([Table 2](#t0010){ref-type="table"}). The full table of biomarker analysis with information about expression in body fluids is available as Supporting Table 1.

![Agarose gel electrophoresis of PCR amplified DNA. Quality control measure for checking amplified DNA requires running agarose gel. Representative samples from patient samples with IDs 1M--8F (as mentioned in the original manuscript [@bb9000]) are provided here along with the positive sample as supplied in the CytoScan HD kit. Negative control is just water in place of DNA.](gr1){#f0005}

![Agarose gel electrophoresis of DNA after fragmentation step. Quality control for DNA after fragmentation step. Representative samples from patient samples with IDs 1M--8F (as mentioned in the original manuscript [@bb9000]) are provided here along with the positive sample as supplied in the CytoScan HD kit. Negative control is just water in place of DNA.](gr2){#f0010}

###### 

Summary of processed samples.

  Sample   Data type        Quality   One copy gain   One copy loss   Two or more copy gain   Two copy loss   LOH   Total CN aberrations
  -------- ---------------- --------- --------------- --------------- ----------------------- --------------- ----- ----------------------
  1M       Affymetrix CEL   0.060     8               12              0                       0               0     20
  2M       Affymetrix CEL   0.105     38              42              2                       0               2     82
  3F       Affymetrix CEL   0.151     15              10              0                       0               0     25
  4F       Affymetrix CEL   0.096     8               10              0                       0               0     18
  5F       Affymetrix CEL   0.169     7               7               2                       0               0     16
  6F       Affymetrix CEL   0.148     19              22              10                      7               9     58
  7M       Affymetrix CEL   0.126     28              48              0                       1               2     77
  8F       Affymetrix CEL   0.071     6               3               0                       0               1     9
  9F       Affymetrix CEL   0.132     27              27              1                       1               4     56
  10F      Affymetrix CEL   0.087     34              49              14                      7               7     104
  11F      Affymetrix CEL   0.105     9               11              0                       0               0     20
  12M      Affymetrix CEL   0.113     28              19              8                       1               1     56
  13M      Affymetrix CEL   0.085     5               12              0                       0               0     17
  14F      Affymetrix CEL   0.174     49              16              3                       0               0     68
  15M      Affymetrix CEL   0.105     9               4               3                       0               1     16

###### 

Biomarker molecules among the driver genes.

  Biomarker gene   Biomarker application
  ---------------- ----------------------------------------------------------------------------------
  ADAM12           Diagnosis
  AGR3             Diagnosis
  AURKA            Efficacy
  BCL2             Diagnosis, efficacy, prognosis
  CLDN7            Unspecified application
  CRP              Diagnosis, disease progression, efficacy, prognosis, safety
  CYP19A1          Diagnosis, efficacy
  DCC              Prognosis
  EXO1             Diagnosis
  FGFR2            Diagnosis, response to therapy
  GSTM1            Diagnosis, efficacy, safety
  HLTF             Diagnosis
  ICAM1            Diagnosis, efficacy, prognosis
  IDO1             Disease progression, efficacy, prognosis
  IGF2BP3          Diagnosis
  IL6              Diagnosis, disease progression, efficacy, prognosis, response to therapy, safety
  IL6R             Efficacy
  INHBA            Diagnosis
  INSR             Prognosis
  MGMT             Diagnosis, efficacy, prognosis
  MS4A1            Efficacy, prognosis
  MUC4             Diagnosis, disease progression
  OVGP1            Diagnosis
  PTGS1            Efficacy
  PTK2             Diagnosis, disease progression, efficacy, prognosis
  PTP4A3           Disease progression
  SLC16A1          Diagnosis
  SMAD4            Prognosis
  STK11            Diagnosis
  TP53             Diagnosis, disease progression, efficacy, prognosis, response to therapy
  ZNF217           Prognosis
